IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 5:30 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 5:30 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
5 Top-Performing S&P 500 Stocks of Q1
by Tirthankar Chakraborty
We have highlighted five S&P 500 stocks that have dished out double-digit returns in Q1 and remained undisturbed by higher bouts of volatility
Why Should You Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX (IDXX) might gain from the commercial launch of Catalyst SDMA Test in North America. As a result, its point-of-care customers can add SDMA as an essential element to the routine chemistry panel.
IDEXX Laboratories Gains on Solid Prospects & CAG Business
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor confidence on strong companion animal business along with growth across all segments.
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
5 of the Best Efficient Stocks for Your Portfolio
by Tirthankar Chakraborty
Companies with a favorable efficiency level are expected to provide impressive returns as efficiency is believed to be positively correlated with price performance.
Second Sight (EYES) Catches Eye: Stock Jumps 12.7%
by Zacks Equity Research
Second Sight (EYES) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
IDEXX Laboratories Strong on CAG Business Amid Currency Woes
by Zacks Equity Research
IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
IDEXX Laboratories (IDXX) Beats on Q4 Revenues, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q4.
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More
by Zacks Equity Research
As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder
by Zacks Equity Research
IDEXX Laboratories (IDXX) already puts its Catalyst SDMA Test to use for hundreds of medical practices across the United States.
5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter (BAX) has been gaining on the back of favorable developments in the regulatory front and product launches.
Intuitive Surgical Banks on da Vinci X, Forex Woes Remain
by Zacks Equity Research
Intuitive Surgical's (ISRG) consistent efforts to boost da Vinci X platform is a positive. However, foreign exchange movements are impacting the company's results
6 MedTech Stocks Set to Crush the Market in 2018
by Zacks Equity Research
Here we take a peek at six MedTech stocks that are expected to post stellar returns in 2018.
Ecolab, Cargill and Techstars Launch Accelerator Program
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key businesses and bolt-on acquisitions to gain market traction and boost profits.
Here's Why You Should Invest in PetMed (PETS) Stock Now
by Zacks Equity Research
PetMed's (PETS) implements strategies to revitalize top line. It also offers a comprehensive portfolio.
IDEXX Laboratories Banks on Global Prospects, CAG Strength
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides on strength across all segments, especially CAG. Strong fundamentals buoy optimism.
Ecolab Focuses on Pest Elimination, Acquires 3 Companies
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key growth businesses and bolt-on acquisitions to gain market traction and boost profits and inorganic growth.
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
by Zacks Equity Research
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
5 of the Most Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.
Here's Why You Should Invest in Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter has witnessed favorable tidings on the regulatory front. The company enjoys strong presence in foreign markets.
Varian's Partners Penn Medicine, Proton Therapy in Focus
by Zacks Equity Research
Varian Medical's (VAR) solid prospects on the proton therapy space holds promise at the moment.
Stryker Gains Ground on MAKO Robotic Unit Amid Forex Woes
by Zacks Equity Research
Solid performance by the MAKO robotic platform has been boosting Stryker's (SYK) revenues for long.